Abstract: The present invention relates to odour improved dermatological or cosmetic preparations comprising N-acetylcysteine and a polyol system containing one or more polyols as masking odour agents. The emulsions of the present invention are useful in the treatment of dermatological disorders or cosmetic skin conditions.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: Composition for topical application in the form of an oil-in-water emulsion containing an oily phase dispersed in an aqueous phase, and a hydrophilic polymer, the composition further containing (1) at least one elastomeric organopolysiloxane and (2) at least one lipophilic compound chosen from lipophilic amino acid compounds and lipophilic salicylic acid compounds. Uses thereof, including topical application to the skin, lips, hair, etc. Stabilization of certain emulsions using a lipophilic compound.

Abstract: Bodywash compositions incorporating high levels of emollient oils and a method for incorporating such high levels of emollient into bodywash compositions.

Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.

Abstract: The invention relates to a silicone-free skin protection composition, in particular a composition to protect against cold, containing the components a.) at least one oil with a pour point in accordance with DIN ISO 30 16 of ??10° C., b.) at least one polyol c.) at least one emulsifier d.) optionally at least one wax, where the viscosity difference in the temperature interval from +4° C. to +50° C. of highest and lowest viscosity of the skin protection composition has a value in the range from 0 to ?20 000 mPas.

Abstract: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

Abstract: A unique, synergistic formulation for the treatment of first-degree skin burns is provided for topical use and alleviates the full spectrum of symptoms and concerns associated with epidermal burns, including pain, blistering, redness, swelling, compromised skin integrity, risk of infection and scarring. The formulation contains natural homeopathic extracts combined with a pharmaceutically acceptable carrier suitable for topical administration. The formulation may include three or more of the following homeopathic extracts: Cantharis Vesicatoria, Echinacea Angustifolia, Calendula Officinalis and Hypericum Perforatum.

Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.

Abstract: The invention provides surfactant-containing cosmetic, dermatological, and pharmaceutical agents comprising at least one water-soluble or water-swellable copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired, a silicon-containing component(s), E) if desired, a fluorine-containing component(s), F) if desired, one or more macromonomers, G) the copolymerization taking place if desired in the presence of at least one polymeric additive, H) with the proviso that component A) is copolymerized with at least one component selected from one of the groups D) to G).

Abstract: The present invention relates to particulate compositions comprising at least 50% of dioleoyl phosphatidyl ethanolamine (DOPE) and 1 to 50% of Polysorbate 80 (P80). All parts are by weight relative to the sum of the weights of a+b and the compositions comprise non-lamellar particles or form non-lamellar particles when contacted with an aqueous fluid. The compositions have advantageous stability and low toxicity and the invention also relates to pharmaceutical compositions thereof.

Abstract: An oil-in-water emulsified sunscreen cosmetic which contains: (A) Containing the following three types of surfactants (A-1)-(A-3); (A-1) A POE stearic ester having a POE mole number of 20-120; (A-2) sorbitan tristearate; and (A-3) glyceryl stearate having a HLB of 5-8; (B) bis-ethylhexyloxyphenolmethoxyphenyltriazine and/or tert-butylmethoxybenzoylmethane, oil soluble ultraviolet absorbents, solid at room temperatures; (C) ethylhexyl methoxycinnamate and/or octocrylene, oil soluble ultraviolet absorbents, liquid at room temperature; (D) phenylbenzimidazolesulfonic acid, a water soluble ultraviolet absorbent; and (E) a higher alcohol having 14-24 carbon atoms.

Abstract: The present invention relates to a water-in-oil emulsified composition containing a sphingosine represented by the following formula (1): (R1 represents a hydrocarbon group optionally having a substituent; Y represents methylene, methine or O; X1, X2 and X3 each represent H, OH or acetoxy group; X4 represents H, acetyl group or the like; R2, R3 each represents H, OH or the like; R represents H, amidino group or the like; and a stands for 2 or 3), (B) a C6-30 fatty acid, and (C) an oil component. This water-in-oil emulsified composition has excellent stability and provides a good feeling to skin upon use.

Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.

Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.

Abstract: Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.

Abstract: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 0.1% to about 5% of a zinc ionophoric material; from about 40% to about 95% water; and wherein the pH of the composition is greater than about 7.

Abstract: The invention provides surfactant-free cosmetic, pharmaceutical, and dermatological compositions comprising at least one copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired, one or more silicon-containing components, E) if desired, one or more fluorine-containing components, F) if desired, one or more macromonomers, G) the copolymerization taking place if desired in the presence of at least one polymeric additive, H) with the proviso that component A) is copolymerized with at least one component selected from one of the groups.

Abstract: Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided.

Abstract: A urinary anti-backflow device is provided which prevents urine from flowing back into the patient's bladder from a urine collection bag. The device comprises a flow tube having an upstream section connectable to an external urinary device secured to a patient and a downstream section connectable to a urine collection bag, a rod within the flow tube, and a stopper which moves along the rod between the downstream and upstream ends of the flow tube. When the upstream section of the flow tube is elevated relative to the downstream section, urine from the patient is free to flow through the flow tube. When the downstream section of the flow tube is elevated relative to the upstream section, urine forces the stopper against the upstream section to prevent backflow.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.

Abstract: Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided.

Abstract: Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided.

Abstract: A concentrate including, by weight (a) 10% to 60%, preferably 25% to 35%, of a saturated fatty acid selected from stearic or palmitic acid, or mixtures thereof, in an adduct of an amidopropyldimethyl-2-hydroxyethyl ammonium halide, with substantially no free acid present, and (b) 40% to 90%, preferably 65% to 75%, of a low molecular weight alcohol or saturated fatty alcohol or alcohols, for use in personal care products, including hair care and skin care compositions.

Abstract: A unique, synergistic formulation for the treatment of first-degree skin burns is provided for topical use and alleviates the full spectrum of symptoms and concerns associated with epidermal burns, including pain, blistering, redness, swelling, compromised skin integrity, risk of infection and scarring. The formulation contains natural homeopathic extracts combined with a pharmaceutically acceptable carrier suitable for topical administration. The formulation includes the following homeopathic extracts: Cantharis vesicatoria, Echinacea anqustifolia, Calendula officinalis and Hypericum perforatum.

Abstract: A process is described for the preparation of storage-stable, multiple emulsions of the water/oil/water (W/O/W) type which comprise one or more active ingredients. The process comprises the steps a) stirring the active ingredient into an aqueous phase, b) emulsifying the aqueous phase by passing the aqueous phase through a large-pored, porous membrane into an oil phase, c) phase inversion of the emulsion from b), by cooling the mixture at a cooling rate of at least 0.3 K/min, where an emulsifier is added either to the aqueous phase in a) or to the oil phase in b) or to both phases.

Abstract: A self-reversible reverse microlatex composition comprising an oil phase, an aqueous phase, a water-in-oil surfactant(s), a oil-in-water surfactant(s) and 15% to 40% by weight by weight of a branched or crosslinked polyelectrolyte. The polyelectrolyte is based on a monomer containing a strong or weak acid function, which is partially or totally salified, a copolymer of at least one monomer containing a strong acid function and at least one monomer containing a weak acid function or at least one neutral monomer, a copolymer of at least one monomer containing a weak acid function and at least one neutral monomer, or a copolymer of at least one monomer containing a strong acid function, a monomer containing at least one weak acid function and at least one neutral monomer. The surfactants have a total HLB number of 8.5 to 11. Uses in cosmetics and as an industrial emulsifier and/or thickener.

Abstract: The invention relates to polyglycerol partial esters of polyricinoleic acid and polyfunctional carboxylic acids, obtainable by esterification of a a) polyglycerol mixture with b) at least one polyricinoleic acid and c) at least one di- and/or tricarboxylic acid and optionally d) at least one fatty acid having 6 to 22 carbon atoms by methods known per se, and to the use thereof for producing cosmetic or pharmaceutical emulsions or dispersions.

Abstract: The present invention provides a pediculicidal and ovicidal composition with an extraordinarily lethal effectiveness that can also be used to remove parasites, such as lice. The pediculicidal and ovicidal composition contains a purified terpene agent such as citronellal, citronellol, citronellyl or a mixture thereof, a short chain alcohol, and a non-aqueous co-solvent and/or surfactant component. The composition more preferably utilizes citronellyl acetate as the active agent. The compositions can be administered topically to humans, animals or any infested areas.

Abstract: A subject matter of the invention is a cosmetic composition comprising a cosmetically acceptable organic liquid medium, a block polymer and a plasticizer, characterized in that: the block polymer is a film-forming linear ethylenic polymer, the plasticizer is a compound, the nature and the amount of which are such that the composition is capable of forming a film having a hardness of less than or equal to 35 seconds, the hardness of the film being measured using a Persoz pendulum according to Standard NF-T-30-016, and in particular a compound having a solubility parameter ?h ranging from 5.5 to 11 (J/cm3)1/2. Application to making-up and caring for keratinous substances, in particular the skin.

Abstract: A nanodispersion comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (?) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (?) adding the liquid obtained in step (?) to the water phase of the pharmaceutical end formulations, where steps (?) and (?) may be carried out without high energy mixing or homogenization. The nanodispersions prepared according to this invention are suitable as transport vehicles for pharmaceutical active agents.

Abstract: Disclosed are mascara compositions containing an aqueous phase, fatty phase, a structuring agent, and a polyurethane/poly(meth)acrylate graft copolymer, and methods of making and using them.

Abstract: The present invention relates to polyglycerol partial esters of polyhydroxystearic acid and polyfunctional carboxylic acids which are obtainable by esterification of a polyglycerol mixture with polyhydroxystearic acid where N=1 to 10, preferably 2 to 8, in particular 3 to 5 units and dimer fatty acids which have been obtained by catalytic dimerization of unsaturated fatty acids having 12 to 22 C atoms and have an average functionality of 2 to 3, and/or with aliphatic, linear or branched dicarboxylic acids having a chain length of 2 to 16 C atoms and additionally saturated or unsaturated, linear or branched fatty acids having 6 to 22 C atoms, preferably 12 to 18 C atoms, the degree of esterification of the polyglycerol mixture being between 20 and 75%, preferably 40 to 70%.

Abstract: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.

Abstract: The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising (i) one or more NO-releasing NSAID(s); (ii) one or more surfactants, of which at least one is phospholipid; said composition forming an in-situ oil-in-water emulsion upon contact with gastrointestinal fluids. The composition may optionally also comprise an additional oil or semi-solid fat. Further, one or more short-chain alcohols can optionally be included in the composition. Also within the scope of the invention is a combination with a proton pump inhibitor. The pharmaceutical composition is useful in the treatment of pain and inflammation. Further within the scope of the invention is kit comprising a pharmaceutical composition according to the invention in a unit dosage form, in combination with a proton pump inhibitor, and said proton pump inhibitor is enteric coated.

Abstract: Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of the pharmaceutically active agent; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier; and wherein the Hsieh enhancer has the following structure: wherein X and Y are oxygen, sulfur or an imino group of the structure or ?N—R with the proviso that when Y is the imino group, X is an imino group, and when Y is sulfur, X is sulfur or an imino group; A is a group having the structure and the remaining variables are defined herein.

Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions.

Abstract: The present invention relates to highly stable water-in-oil sunscreen emulsions that provide a high sunscreen efficiency (“SE”) having a sun protection factor (“SPF”) of X, where X is at least about 15, and having a sunscreen efficiency (“SE”) of at least 2, preferably at least 3, where SE is the ratio of SPF over the total weight percentage of sunscreen actives based on the total weight of the composition. The emulsions of the present invention provide photoprotection for the period corresponding to the labeled SPF throughout the period of exposure to natural sunlight and comprises (i) at least one sunscreen active and (ii) an alkyl dimethicone copolyol emulsifier in which the water-soluble, alkyl-soluble and silicone-soluble groups of the dimethicone copolyol are in specific ratios to each other. Preferably, the high SE water-in-oil emulsion comprises both a UV-A sunscreen and UV-B sunscreen. More preferably, the combination of sunscreen actives is photostable.

Abstract: The present invention relates to pigmented emulsion cosmetic compositions containing emulsifying silicone elastomers that provide a natural appearance to the skin upon application. In particular, these cosmetic compositions are formulated such that agglomeration of the pigment upon application to the skin is minimized.

Abstract: A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.

Abstract: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.

Abstract: A topical deodorant composition comprising unrefined Shea butter, sodium bicarbonate, cornstarch, cocoa butter, coconut oil, lavender oil, Clary sage oil, benzoin gum tincture and vitamin E. The topical deodorant composition controls body odor and improves the moisture, texture and appearance of the skin. To prepare the topical deodorant composition, unrefined Shea butter, cocoa butter, coconut oil and vitamin E are mixed over hot water at 100° F.-120° F. Cornstarch and sodium bicarbonate are added over hot water at 100° F.-120° F. Subsequently, lavender oil, Clary sage oil and benzoin gum tincture are added. The mixture is removed from heat, cooled to 75° F. and distributed via a glass jar, solid stick or squeezable tube.

Abstract: An aqueous suspension, stable in physiological medium, of nanoparticles for delivering active principles such as insulin. The delivery particles are based on a three-block copolymer: polyethylene glycol/hydrophilic polyaminoacid/hydrophobic polyaminoacid. These three-block copolymers can be associated with an active principle without denaturing it, and perform a controlled and long-term release of the active principle in vivo, and thus provide the active principle with a very prolonged release. Also disclosed is a powder form solid from which are derived the delivery particles, the preparation of the powder-form solid, a suspension of delivery particles based on the three-block copolymer, and pharmaceutical specialties obtainable from the delivery particles filled with active principle.

Abstract: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.

Abstract: The invention relates to compositions having enhanced post wash hydration by ensuring component or components of the composition meet selected defined criteria.

Abstract: A stable complex oil-in-water emulsion which is useful in the cosmetic, pharmaceutical or food fields. The stable complex oil-in-water emulsion is formed by the mixing of individual oil-in-water emulsions, each individual emulsion being obtained from an air/water pre-emulsion of a preferably-nonionic surfactant; a cosurfactant selected from hydrophilic compounds, preferably with at least one hydroxyl group selected from polyols; and an aqueous phase. A method of preparing a stable complex oil-in-water emulsion whereby individual oil-in-water emulsions, chosen for properties desired in the stable complex oil-in-water emulsion, are optionally diluted and mixed without exerting a shear force.

Abstract: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.

Abstract: A cosmetic or dermatological composition comprising at least one gradient copolymer comprising at least two different monomers, displaying a mass polydispersity index (Ip) less than or equal to 2.5 and for example, additionally a low composition polydispersity. A cosmetic or dermatological method for make-up or care of keratinous substances, notably the skin of the body or of the face, the nails, the hair and/or the eyelashes, comprising application of a cosmetic composition as defined above on the said substances.